285 related articles for article (PubMed ID: 37149594)
1. Tumor residue in patients with stage II-IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein-Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose.
Huang YY; Zhou JY; Zhan ZJ; Ke LR; Xia WX; Cao X; Cai ZC; Deng Y; Chen X; Zhang LL; Huang HY; Guo X; Lv X
BMC Cancer; 2023 May; 23(1):410. PubMed ID: 37149594
[TBL] [Abstract][Full Text] [Related]
2. Integrating pretreatment MRI-detected nodal features and Epstein-Barr virus DNA to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma.
Guo J; He Y; Lin C; Jiang Q; Xing HW; Zhang YC; Shen GZ; Lin HX; Guo L; Yang Q
Oral Oncol; 2023 Nov; 146():106574. PubMed ID: 37741017
[TBL] [Abstract][Full Text] [Related]
3. Integrating Postradiotherapy MRI-Detected Lymph Node Necrosis and Pre- and Posttreatment Epstein-Barr Virus-DNA for Risk Stratification in Nasopharyngeal Carcinoma.
Cao D; Li S; Li H; Liu L; Wang X; Quan T
J Magn Reson Imaging; 2023 Jul; 58(1):108-119. PubMed ID: 36326089
[TBL] [Abstract][Full Text] [Related]
4. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
5. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
[TBL] [Abstract][Full Text] [Related]
6. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ
Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900
[TBL] [Abstract][Full Text] [Related]
7. Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy.
Hui EP; Li WF; Ma BB; Lam WKJ; Chan KCA; Mo F; Ai QYH; King AD; Wong CH; Guo R; Poon DMC; Tong M; Li L; Lau TKH; Wong KCW; Lam DCM; Lo YMD; Ma J; Chan ATC
Ann Oncol; 2020 Jun; 31(6):769-779. PubMed ID: 32217076
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
[TBL] [Abstract][Full Text] [Related]
9. Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort Study.
Chen QY; Guo SY; Tang LQ; Lu TY; Chen BL; Zhong QY; Zou MS; Tang QN; Chen WH; Guo SS; Liu LT; Li Y; Guo L; Mo HY; Sun R; Luo DH; Zhao C; Cao KJ; Qian CN; Guo X; Zeng MS; Mai HQ
Cancer Res Treat; 2018 Jul; 50(3):861-871. PubMed ID: 28903550
[TBL] [Abstract][Full Text] [Related]
10. Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma.
Lee VH; Kwong DL; Leung TW; Choi CW; Lai V; Ng L; Lam KO; Ng SC; Sze CK; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; Khong PL
Oncotarget; 2017 Jan; 8(3):5292-5308. PubMed ID: 28029657
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
[TBL] [Abstract][Full Text] [Related]
12. Elevated plasma fibrinogen level shows superior prognostic value than Epstein-Barr virus DNA load for stage IVA/B nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era.
Lan M; Chen C; Huang Y; Mao M; Han F; Liao J; Deng M; Duan Z; Zheng L; Wu S; Lu T; Jian Y
Oncotarget; 2016 Jul; 7(29):46242-46252. PubMed ID: 27323828
[TBL] [Abstract][Full Text] [Related]
13. Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin.
Hua L; Chen S; Wei M; Shen Y; Long J; Lin Z; Meng Y; Guo C; Huang H; Tu X; Yao M
Cancer Biother Radiopharm; 2022 Feb; 37(1):2-10. PubMed ID: 33764811
[No Abstract] [Full Text] [Related]
14. Nomograms for predicting survival outcomes in intensity-modulated radiotherapy era of nasopharyngeal carcinoma: A study based on Epstein-Barr virus DNA biological responses.
Yang K; Li M; Zhu J; Zeng L; Tian J; Xie W; Shou A; Li Y; Li G
Head Neck; 2021 Jun; 43(6):1838-1847. PubMed ID: 33605501
[TBL] [Abstract][Full Text] [Related]
15. MRI-detected residual retropharyngeal lymph node after intensity-modulated radiotherapy in nasopharyngeal carcinoma: Prognostic value and a nomogram for the pretherapy prediction of it.
Li WZ; Liu GY; Lin LF; Lv SH; Qiang MY; Lv X; Wu YS; Liang H; Ke LR; Wang DL; Yu YH; Qiu WZ; Liu KY; Guo X; Li JP; Zou YJ; Xiang YQ; Xia WX
Radiother Oncol; 2020 Apr; 145():101-108. PubMed ID: 31931288
[TBL] [Abstract][Full Text] [Related]
16. Significance of boost dose for T4 nasopharyngeal carcinoma with residual primary lesion after intensity-modulated radiotherapy.
Fei Z; Xu T; Qiu X; Li M; Chen T; Li L; Huang C; Chen C
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2047-2055. PubMed ID: 33392660
[TBL] [Abstract][Full Text] [Related]
17. Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma.
Tang LQ; Li CF; Li J; Chen WH; Chen QY; Yuan LX; Lai XP; He Y; Xu YX; Hu DP; Wen SH; Peng YT; Zhang L; Guo SS; Liu LT; Guo L; Wu YS; Luo DH; Huang PY; Mo HY; Xiang YQ; Sun R; Chen MY; Hua YJ; Lv X; Wang L; Zhao C; Cao KJ; Qian CN; Guo X; Zeng YX; Mai HQ; Zeng MS
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26467665
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era.
Chen WH; Tang LQ; Guo SS; Chen QY; Zhang L; Liu LT; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
Medicine (Baltimore); 2016 Feb; 95(5):e2642. PubMed ID: 26844482
[TBL] [Abstract][Full Text] [Related]
19. Cigarette smoking complements the prognostic value of baseline plasma Epstein-Barr virus deoxyribonucleic acid in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy: a large-scale retrospective cohort study.
Lv JW; Chen YP; Zhou GQ; Tang LL; Mao YP; Li WF; Guo R; Lin AH; Ma J; Sun Y
Oncotarget; 2016 Mar; 7(13):16806-17. PubMed ID: 26919237
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
Zhang WR; Du YY; Guo CY; Zhou HX; Lin JY; Meng XH; Mo HY; Luo DH
Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]